SCHEMBL29977664

SCHEMBL29977664

O=C1c2ccccc2C(=O)N1Cc1cc(F)c(Br)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.47
CASP3 P42574 2/20 0.44
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CYP1B1 Q16678 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565213 1.00 CHRM5 (0.47) CHRM5CASP3HTTMEN1ALDH1A1
SCHEMBL14723531 0.78 CHRM5 (0.53) CHRM5CASP3HTTMEN1ALDH1A1
SCHEMBL29546032 0.77 CHRM5 (0.47) CHRM5CASP3HTTMEN1ALDH1A1
SCHEMBL18555560 0.77 CHRM5 (0.47) CHRM5CASP3HTTMEN1ALDH1A1
SCHEMBL2578279 0.75 CASP3 (0.51) CHRM5CASP3ALDH1A1HSD17B10TYR
SCHEMBL29629115 0.75 GRM5 (0.52) CASP3CA12CA1CA2CA9
SCHEMBL29411210 0.75 GRM5 (0.51) CHRM5CASP3ALDH1A1MAPTTYR
SCHEMBL5957957 0.75 TP53 (0.58) CHRM5CASP3GRM5
SCHEMBL8220060 0.75 CASP3 (0.55) CHRM5CASP3HTTALOX15KMT2A
SCHEMBL17979154 0.75 GRM5 (0.51) CHRM5CASP3ALDH1A1MAPTTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 US disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 EP disclosed
WO-2022235945-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. (US) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN CHRM5 4598/4885CASP3 3634/4885HTT 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.